Pharmaceuticals News

ASSEMBLÉE GÉNÉRALE MIXTE DU 29 AVRIL 2026 MODALITÉS DE MISE À DISPOSITION OU DE CONSULTATION DES DOCUMENTS PRÉPARATOIRES Les actionnaires de la Société sont invités à participer à l’assemblée...

  COMBINED GENERAL MEETING OF APRIL 29, 2026 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday April 29,...

 - Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs)  - ADS holders will receive one ordinary share listed on Nasdaq...

A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain...

23andMe Research Institute Study, Published in Nature, Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects

Spider silk’s extraordinary combination of strength, elasticity, toughness, biocompatible, biodegradable, and low weight, properties that outperform Kevlar

China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs).

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

Mesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue milestone since launch last year Showcases transformative blockbuster products for...

Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high...